Highlights
Profile claimed by owner
About
Targeted Protein Degradation Drug Discovery
ApoRx is a drug-discovery company focusing on the discovery, design, characterization, and development of small proteolysis-targeting molecules against well-validated disease-causing proteins in cancer and other indications. The core of its technology is the Aperion library, a proprietary focus library of RING E3 ligase binders that is designed to harness the intracellular ubiquitin-proteasome machinery to degrade and destroy unwanted proteins via targeted protein degradation. ApoRx is a subsidiary of Agbiopro Protein Degradation Hub, a management and consulting firm.
Identity
| Name | ApoRx Biopharmaceuticals |
|---|---|
| Slug | aporx-biopharmaceuticals-ltd |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Ovs_OIJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Ness Ziona, Israel |
Web & social
| Website | https://www.aporxbio.com/ |
|---|---|
| https://www.linkedin.com/company/70961472 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
oncologypharmaceuticalsimmunotherapypharma-companiesbiotechnologydrug-discoverydrug-designbiopharmaceuticalcancer-therapycancer
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}